You are here
Single Embryo Transfer with Chromosome Screening Superior to Double Embryo Transfer
October 25, 2012
Findings from a clinical trial examining single embryo transfer (SET) with comprehensive chromosome screening (CCS) indicate increased in vitro fertilization (IVF) success rates compared to traditional double embryo transfer (DET).
Reproductive Medicine Associates of New Jersey presented at the 68th Annual Meeting of the American Society for Reproductive Medicine. Their clinical trial, Blastocyst Euploid Selective Transfer (BEST) is the first well-controlled trial of its kind showing SET combined with CCS is a more accurate method for determining embryo quality as compared to a morphology, or appearance, based examination.
Researchers claim this superior screening method will encourage single embryo transfers while producing pregnancy rates equivalent to double embryo transfers which has been the protocol for highest IVF success rates over the last 25 years. This will reduce the prevalence of multiple pregnancies and thereby decrease health risks to the mother and fetus.
"This is the first time that a single embryo transfer trial has shown equal, and in fact better, outcomes than a traditional morphology-based double embryo transfer," said Eric J. Forman, M.D., lead investigator. "Advances in screening technology that allow us to rapidly and safely determine if an embryo is chromosomally normal now make SET a more viable pathway to pregnancy for couples undergoing IVF, while reducing the risk of complicated and costly multiple gestations. With accuracy rates up to 97%, our CCS technology platform helps make the promise of one embryo one healthy baby a reality."
Founding partner of RMANJ, Richard T. Scott, Jr., M.D., F.A.C.O.G., H.C.L.D., added, "The most common and costly complication of IVF is multiple pregnancies and births. The BEST strategy shows that we can eliminate the complications associated with [assisted reproductive technologies] ART, while simultaneously improving delivery rates, reducing time-in-treatment for patients, and reducing overall costs. It is really a home run in every area."
Click here to read more.